.navbar .collapse { display: block; } .mobile-nav { max-height: none !important; } @media screen and (min-width: 1200px) { .navbar #basic-navbar-nav .navbar-nav { position: static !important; } }

Hyunseok Kang, MD

Articles

Exploring Real-World Evidence Presented at ATA 2023

April 26th 2024

Medical professionals discuss the recently published real-world evidence presented at the American Thyroid Association 2023 Conference.

Determining Which DTC Patients May Benefit from Systemic Therapy

April 26th 2024

Hyunseok Kang, MD, discusses the importance of balancing toxicities and other factors when initiating first-line treatments for patients with refractory differentiated thyroid cancer (DTC), while emphasizing the need to set clear goals and communicate potential adverse reactions before allowing patients to make informed decisions.